Naomi B. Haas, MD
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
Fax: 215-349-8550
Email:
naomi.haas@uphs.upenn.edu
naomi.haas@uphs.upenn.edu
Education:
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
B.S. (Integrated Life Sciences)
Kent State University, 1985.
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
B.S. (Integrated Life Sciences)
Kent State University, 1985.
Post-Graduate Training
Resident, Abington Memorial Hospital, 1985-1988.
Fellow, Temple University/Fox Chase Cancer Center, 1988-1991.
Fellow, Fox Chase Cancer Center- Institute for Cancer Research, 1992-1995.
Fellow, Fox Chase Cancer Center, 1995-2000.
Resident, Abington Memorial Hospital, 1985-1988.
Fellow, Temple University/Fox Chase Cancer Center, 1988-1991.
Fellow, Fox Chase Cancer Center- Institute for Cancer Research, 1992-1995.
Fellow, Fox Chase Cancer Center, 1995-2000.
Certifications
American Board of Internal Medicine, 1988.
American Board of Internal Medicine, Medical Oncology, 1995.
Medical Oncology Recertification, 2005.
Permanent linkAmerican Board of Internal Medicine, 1988.
American Board of Internal Medicine, Medical Oncology, 1995.
Medical Oncology Recertification, 2005.
Selected Publications
Yu JQ, Milestone BD, Parsons RB, Doss M, Haas N: Findings of Intra-Mediastinal Gossypiboma with F-18 FDG PET in a Melanoma Patient. CLinical Nuclear Medicine 33(5): 344-345, 2008.Dreicer, R., Li, S., Manola, J., Haas, N.B., Roth, B.J., Wilding, G.: A Phase II Trial of Epothilone B Analogue BMS-247550 (Ixabepilone) in Advanced Carcinoma of the Urothelium (E3800): A Trial of the Eastern Cooperative Oncology Group. Cancer 110(4): 759-763, 2007.
Wong, Y.N., Suh, B., Parsons, R., Telivala, B., Haas, N., Greenberg, R.: Emphysematous pyelonephritis caused by Pasteurella multocida following renal embolization for renal cell cancer: A case report, in press. 2007.
Haas, N.B. and Uzzo, R.G.: A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma,US Genito-urinary Disease. ECOG 2805(2), 2007.
Haas, N.B. and Uzzo, R.G.: A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma,US Genito-urinary Disease. 2007.
Haas, N.B., and Uzzo, R.G.: Targeted Therapies for Kidney Cancer in Urologic Practice. Urologic Oncology 25(5): 420-432, 2007.
Houghton, A.N., Coit, D.G., Daud, A., Dilawari, R.A., Dimaio, D., Gollob, J.A., Haas, N.B., Halpern, A., Johnson, T.M., Kashani-Sabet, M., Kraybill, W.G., Lange, J.R., Martini, M., Ross, M.I., Samlowski, W.E., Sener, S.F., Tanabe, K.K., Thompson, J.A., Trisal, V., Urist, M.M., Walker, M.J. : Melanoma. Journal of the National Comprehensive Cancer Network 4(7): 666-684, 2006.
Yao, K., Gietema J.A., Shida S., Selvakumaran M., Fonrose, X., Haas, N.B., Testa, J., O’Dwyer, P.J.: Macrophage Migration Inhibitory Factor (MIF) is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clinical Cancer Research 11(20): 7264-7272, 2005.
Yao, K., Gietema, J.A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N.B., Testa, J., O'Dwyer, P.J.: In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. British Journal of Cancer 93(12): 1356-1363, 2005.
Rowinsky, E., Schwartz, G., Gollob, J., Thompson, J., Vogelzang, N., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.P., Arends, R., Foon,, K., Schwab, G., Dutcher, J.: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Journal of Clinical Oncology 22: 3003-3015, 2004.
